All In Biotech

Drug Trial Radar · NCT07216027

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

Nov 20, 2025

Primary completion

Feb 2, 2028

Study completion Feb 2, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. Are 18 to 64 years of age; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD. The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.

Conditions

  • Atopic Dermatitis
  • Eczema, Atopic

Interventions

  • PF-08049820Drug

    Tablet

  • PlaceboDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in Eczema Area and Severity Index (EASI) total score at Week 12Time frame: Week 12

Locations

52 sites in 9 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona · Recruiting

  • Mayo Clinic Specialty Building

    Phoenix, Arizona · Recruiting

  • Mayo Clinic

    Scottsdale, Arizona · Recruiting

  • Marvel Clinical Research

    Huntington Beach, California · Recruiting

  • Metropolis Dermatology - DTLA

    Los Angeles, California · Not yet recruiting

  • Northridge Clinical Trials

    Northridge, California · Recruiting

  • Clinical Science Institute

    Santa Monica, California · Recruiting

  • Gsi Clinical Research

    Margate, Florida · Recruiting

  • Skin Research of South Florida

    Miami, Florida · Active not recruiting

  • Montefiore - Jacobi Dermatology Clinic

    The Bronx, New York · Recruiting

  • Montefiore - Clinical Research Center

    The Bronx, New York · Recruiting

  • Montefiore - Greene Medical Arts Pavillion

    The Bronx, New York · Recruiting

  • Montefiore - The Dermatology Center

    The Bronx, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Apex Clinical Research Center, LLC. - Lorain

    Lorain, Ohio · Recruiting

  • Apex Clinical Research Center, LLC.

    Mayfield Heights, Ohio · Recruiting

  • Paddington Testing Co, Inc

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Department of Dermatology

    Pittsburgh, Pennsylvania · Recruiting

  • Diagnostic Consultative Center "Ascendent"

    Sofia, Bulgaria · Not yet recruiting

  • ASMC - IPSMC - skin and venereal diseases

    Sofia, Sofia (stolitsa), Bulgaria · Not yet recruiting

  • Diagnostic Consultative Centre (DCC) - Foкus 5

    Sofia, Sofia (stolitsa), Bulgaria · Not yet recruiting

  • Centre de Recherche Saint-Louis inc.

    Québec, Canada · Recruiting

  • Dermatology Research Institute

    Calgary, Alberta, Canada · Recruiting

  • Toronto Research Centre

    Toronto, Ontario, Canada · Recruiting

  • Peking University People's Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

  • Guangdong Province Dermatology Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • DERMAMEDICA s.r.o.

    Náchod, Czechia · Recruiting

  • CCR Ostrava, s.r.o.

    Ostrava, Czechia · Recruiting

  • Pratia Czech s.r.o.

    Pardubice, Czechia · Recruiting

  • Pratia Czech s.r.o.

    Prague, Czechia · Recruiting

  • Hopital Saint Louis

    Paris, France · Not yet recruiting

  • Hopital Charles Nicolle

    Rouen, France · Recruiting

  • Hopital Larrey

    Toulouse, France · Not yet recruiting

  • University Hospital Schleswig-Holstein

    Kiel, Germany · Not yet recruiting

  • Universitätsklinikum Münster

    Münster, North Rhine-Westphalia, Germany · Not yet recruiting

  • Universitätsklinikum Schleswig-Holstein

    Lübeck, Schleswig-Holstein, Germany · Not yet recruiting

  • Hattori Dermatology Clinic

    Takasaki, Gunma, Japan · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.